JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

A Comprehensive Review of Controlled Drug Delivery System

Mr. Rahul. I. Jadhav[1], Mr. Bhimashankar. K. Bhui[2], Aditya Anil Shelake[3], Aarti Ashok Rokade[4], Aarti Vikas Panche[5],

Department of Pharmaceutics, Lokmangal Collage Of Pharmacy, Wadala, Solapur, Maharashtra, India

Abstract:

Controlled drug delivery systems ensure a consistent medication concentration at the absorption site, enabling the homeostasis levels inside the optimal range. This but also reduces side effects but also lessens the need for frequent management. Prolonged release mouth-administered product offer a distinct benefit compared to traditional medication form. They optimize drug attributes, minimizing dosing frequency to a point where a once-daily dose effectively manages therapeutic needs. This approach ensures uniform plasma concentration, maximizing drug utility while minimizing specific and general adverse reactions. It accelerates the treat or manage of conditions in the minimal duration using the little medication amount, promoting greater patient compliance. creation of a regulated drug delivery rate-speed aims to address challenges linked to traditional drug delivery methods. These systems administer the drug at a predefined rate, either locally or throughout the entire system, over a designated duration. Regulated delivery formulations decrease the necessary daily dosing frequency. Over the last two decades, there has been significant progress in regulated medication release mechanism, spanning from comprehensive-scale to nano-scale, incorporating smart precision delivery strategies. Controlled or modified release drug delivery systems enable the gradual administration of drugs over an extended duration. These systems encompass various dosage forms, including those for oral and transdermal use, as well as injectable and implantable options. Although the oral route is generally the preferred method for drug administration, some chemical compounds face challenges like low bioavailability due to solubility or permeability issues.

Keywords:

Controlled Drug Delivery System, Transdermal Drug Delivery System, Factors affecting CDDS, Polymers in CDDS

I. Introduction:

For maximum effectiveness in treatment and fewest potential side effects, controlled drug delivery systems are essential. These systems provide the best possible drug concentrations at the specified areas by

accurately regulating the release of the drug. Different technologies have been used to provide regulated drug delivery, such as hydrogels, liposomes, nanoparticles, and microparticles. In order to enable triggered release in response to certain stimuli, researchers have investigated the merging of smart polymers with responsive materials[1]. Integrating a polymer with a medication or active agent allows for controlled administration of medicines through the ability to prearranged release from the bulk material. Sometimes, the terms "controlled" and "sustained release" are used interchangeably, which can be misleading.. They do, however, reflect different delivery methods. Any dose type showcasing therapeutic control—whether it be temporal, spatial, or both—that administers drug over an extended period of time is considered sustained release. While gradual first-order drug provision is the goal of sustained release systems, zero-order release is usually not achieved. Adjusting the pharmacokinetics and pharmacodynamics of active compounds is the most important objective of controlled prescription drugs delivery. This is achieved by novel drug delivery techniques or by manipulating physiological factors and molecular structures. [2].

A pharmaceutical drug, also known as an Active Pharmaceutical Ingredient, is a recognized substance in official pharmacopoeia designed for diagnosing, curing, mitigating, treating, or preventing diseases, as defined by the FDA. Drug delivery involves strategically administering medication to enhance drug concentration in specific body areas. The primary goal of any drug delivery system is to extend, localize, and target the therapeutic agent specifically within diseased tissues by implementing a controlled and precise interaction.. Each dosage form comprises the drug or API and nondrug components known as excipients or additives. APIs constitute the essential chemical elements responsible for treating diseases[3]. Various administration routes exist for drugs; nevertheless, among them, the oral method stands out as the most convenient for both administering and adjusting dosages. Its widespread acceptance can be mainly attributed to its convenient application and the ease with which it can be prepared on an industrial scale. [4].

II. History of Control Drug Delivery System:

The Journal of Controlled Release (JCR) was founded in 1984, and in the first editorial, its founding editors, Jorge Heller and Jan Feijen, outlined their clear aim [1]. Their goal was to make JCR the leading venue for scientists studying drug delivery to present their ideas in the form of excellent publications. Ever since its founding, JCR has developed into one of the leading journals in the fields of drug delivery and pharmaceutics. The pivotal factor behind its success has been an unwavering commitment to high-quality research—a tradition maintained by Colin G. Pitt, who assumed the role of Editor-in-Chief in 1996, succeeding the Founding Editors and serving until 2005.Over the years, the volume of published content in JCR has steadily risen, as illustrated in Fig 1. The publication consistently receives a surplus of manuscripts, employing stringent criteria for publication, focusing on the excellence and originality of the presented research. JCR's impact factor, which reached 7 in 2013 and elevated it to the top ranking among research publications in pharmaceutics and drug delivery, is another indication of the publication's influence on the field. The journal's success is due in large part to the constant commitment of its writers and their work, the self-sacrificing work of its reviewers, and the endover of all of the editors throughout the three decades earlier[5].

It's fascinating to observe the evolution of drug delivery over the last 60 years, transitioning from the first generation's emphasis on oral and transdermal formulations with controlled release technologies to the second generation's focus on advanced systems like zeroorder release and environment-sensitive delivery using smart polymers and hydrogels. The progress reflects a dynamic field adapting to emerging technologies and scientific advancements[5].

A. Distinguishing 1 Generation and 2 Generation drug delivery technologies

Distinguishing 1 Generation and 2 Generation drug delivery technologies reveals critical disparities. The evolution towards 3G technologies, though ongoing, necessitates an examination of why many 2 Generation advancements haven't transitioned into clinical products. The notable triumphs of 1 Generation

technology primarily stem from oral and transdermal drug delivery systems. Within these formulations, the substantial impact on in vivo pharmacokinetics is achieved by strategically manipulating in vitro drug release kinetics[5].

Sr. No	Year	Title of Top Cited Paper
1.	1984	Insulin in powder form designed for nasal use.
2.	1985	The characteristics of polymers adhering to soft tissue, examining surface, interfacial, and molecular aspects.
3.	1986	Thermally reversible hydrogels: II. Transport and targeted extraction of substances from water-based solutions.
4.	1987	A straightforward formula to depict solute release II. Fickian and non-traditional release from expandable devices.
5.	1988	Release modulation based on pH in copolymer hydrogels with hydrophobic and polyelectrolyte components.
6.	1989	Diffusion of solute and penetrant in expandable polymers. IX. Understanding the mechanisms behind drug release from systems controlled by pH-sensitive swelling.
7.	1990	Regulated vaccine delivery in gut-related lymphoid tissues. I. Biodegradable microspheres administered orally target the Peyer's patches.
8.	1991	An innovative method to create pH-sensitive hydrogels for delivering drugs to the enteric system.
9.	1992	A novel category of drug carriers: Micelles formed by block copolymers of poly(oxyethylene) and poly(oxypropylene) as microcontainers for targeted drug delivery from the bloodstream to the brain
10.	1993	Using block copolymer micelles as carriers for delivering drugs.
11.	1994	Improved accumulation in tumors and extended circulation periods for micelle-forming conjugates of poly(ethylene oxide-aspartate) block copolymer with adriamycin.
12.	1995	Assessing the cytotoxic effects of macromolecules using various in vitro cell culture systems.

13.	1996	Exploring the potential of mucoadhesive polymers to improve the absorption of intestinal peptide drugs. III: Evaluating the impact of chitosan-glutamate and carbomer on epithelial tight junctions in vitro
14.	1997	Examining the physicochemical properties of lipid nanoparticles and assessing both their drug loading capability and potential for sustained release.
15.	1998	Using chitosan and depolymerized chitosan oligomers as carriers for condensing plasmids in in vivo delivery.
16.	1999	Investigating pharmaceutical loading and release characteristics of water-soluble drugs in PLGA nanoparticles prepared through nanoprecipitation.
17.	2000	Exploring the correlation between structure and in vitro biocompatibility of dendrimers, along with initial investigations into the in vivo biodistribution of 125I-labeled polyamidoamide dendrimers
18.	2001	The manufacturing, personality development, and transfection efficiency assessments for chitosan-DNA nanoparticles for gene delivery.
19.	2002	tetracycline hydrochloride release from electrospun poly(ethylene-co-vinylacetate), poly(lactic acid), and polymer blend is being investigated..
20.	2003	Comparing the physical and chemical features, transfection efficacy, and in vivo distribution of low-molecular-weight polyethylenimine with that of high-molecular-weight polyethylenimine with the objective to assess it as a non-viral vector for DNA delivery.
21.	2004	Doxorubicin is delivered using micellar carriers made from poly(ε-caprolactone) and poly(ethylene glycol) block copolymers..
22.	2005	Creating, characterizing, and applying block copolymer micelles for drug delivery.
23.	2006	Gold nanorods modified with PEG to impart stealth properties for in vivo applications.
24.	2007	Microneedles coated for transdermal delivery.
25.	2008	Utilizing albumin as a drug carrier through the design of prodrugs, drug conjugates, and nanoparticles.
26.	2009	Investigating the intracellular fate and cellular absorption mechanism of hydrophobic glycol chitosan-modified nanoparticles.

27.	2010	Exploring the impact of size and shape on the biodistribution of particles injected intravascularly
28.	2011	Nano-vehicles responsive to glutathione, showing promise as a platform for targeted delivery of drugs and genes into cells.
29.	2012	Using magnetic resonanceIn a rabbit Vx2 tumor model, temperature-sensitive liposomes and guided high-intensity focused ultrasound are employed for image-guided medication delivery.. [5]

III. Note On Terminology Of Control Drug Delivery System:

Controlled drug delivery refers to dosage forms utilizing membrane technology to regulate the emission rate of drugs post-administration. In conversely, conventional medication form rely on dissolution, often resulting in quick liberation within a limited segment of the dosing timeline. The term 'sustained release' or 'slow release' denotes an intermediate category, where formulators aim to mitigate initial high release rates and slow subsequent declines. Ad hoc terminology and marketing claims have led to a lack of widely recognized terms or standards distinguishing rate-controlled pharmaceutical delivery systems. Alejandro Zaffaroni, a pioneer in the field, coined the term 'therapeutic system' for pharmaceuticals delivering drugs at aat a predetermined in vivo pace over a defined duration. ALZA Corporation, founded by Zaffaroni in 1968, introduced pioneering products with the therapeutic system designation in the US market. While continuous-rate drug delivery mechanism are ideal, they are only achievable with non volatile medication administered through infusion pumps. Tablet/compact dosage form typically exhibit a time sequence of rates, starting and ending at zero, with nearly constant or gradually declining rates in between. The term 'constant-rate' is generally applied when a a significant majority of the drug administration maintains a nearly constant pace, but differing views on characterizing time-varying rates exist. Not all drugs benefit from a constant delivery rate, such as nitroglycerin, which exhibits tolerance. Tolerance challenges the assumption that constant-rate delivery is optimal for most drugs. Research on drug is consistently delivered at a steady rate patterns of varying rates, aiming to reduce receptor desensitization linked to tolerance, is not a prominent focus in contemporary pharmacodynamics. The controlled drug delivery field initially assumed constant-rate delivery as the desired pattern, with most products approximating continuous, constant-rate drug delivery, except for transdermal Nitroglycerin [6].

A. Quick-acting dosage form:

These are traditonal medication form releasing the drug upon administration for swift and thorough systemic uptake. Post-assimilation of the drug plasma concentration follows its pharmacokinetic profile, gradually decreasing below the minimum therapeutic concentration (MEC), leading to the cessation of therapeutic activity. The duration of action denotes the period maintaining therapeutic level, and the onset of action marks when the maximum concentration is achieved. Maintaining a steady-state concentration requires subsequent doses, resulting in a ‘Teeter-totter’ crest and trough pattern. Fluctuations in drug concentration magnitudes vary based on factors like absorption rate, distribution, elimination, and dosing intervals.

B. Modified release dosage form:

These medication deviate from the conventional type by featuring a distinct rate and timing of drug release. Referred to as modified release dosage forms, they include examples like enteric-coated tablets. An

illustrative instance is an enteric-coated tablet designed to prevent the stomach's decomposition of drugs like erythromycin. Taking this concept further, multi-layered tablets represent a more advanced form of modified release delivery systems.

C. Site-Specific targeting:

These mechanisms involve directing the drug administration precisely to a specific living site, often located neighboring to or within the affected organ or tissue.

D. Targeting Receptors:

These approaches involve directing drugs toward specific biological receptors. Here, the goal is to reach the target receptor associated pharmaceutical agent localized in an organ or tissue. Both precision targeting" or "targeted delivery system fulfill the geographical dimension of drug delivery and are classified as sustained drug delivery systems.

E. Extended Release Formulation:

Unlike immediate release or conventional dosage forms, a prolonged-release dosage doesn't promptly release the drug upon administration. Instead, administer the drug gradually at predetermined intervals or times. Nevertheless, in certain instances, a fraction of the drug may be promptly released upon administration.

F. Extended-release dosage form:

If a dosage form reduces the frequency of administration by at least two times when compared to immediate release or conventional forms, it is classified as an extended-release dosage form. Long-acting, controlled-release, and sustained-release dose forms fall under this group.

G. Continuous Release Formulation:

Sustained release dosage forms ensure that the drug is released at a controlled rate with stable drug concentration within the organism for an extended duration. The release rate of the drug adheres to exponential decay kinetics. Typically, the drug content in a single dose of sustained release formulation exceeds that of its conventional or immediate release counterpart.

H. Extended Duration Dosage Form:

Within this dosage form, the drug is released at a comparatively slower rate, ensuring a prolonged therapeutic action. This formulation involves the immediate release of one drug dose upon administration, followed by the subsequent release of a second dose at a later stage[7].

IV. Types of Control Drug Delivery System

1. Muccoadhesive Delivery System
2. Transdermal Drug Delivery System
3. Impactable Drug Delivery System
4. Injectable Drug Delivery Systems
5. Inhalational Drug Delivery System
6. Targeted Drug Delivery System

1. Muccoadhesive Drug Delivery System

Mucoadhesive drug delivery systems enhance drug retention at mucosal surfaces, improving therapeutic efficacy. These systems utilize bioadhesive polymers that adhere to mucosal tissues, extending drug contact time. An example is buccal patches for controlled drug release[8].

Anotomy And Physiology of Oral Cavity

In the human body, food and air enter through the mouth. It is bounded by the glottis, lips, cheeks, hard and soft palates, and the neck. It is made up of the tongue, a large muscle that is connected to the floor of the mouth by the frenulum linguae, and the vestibule, the area between the teeth and cheeks. The mouth is essential for speech creation in addition to its function in food intake.

Key components include teeth for food breakdown, the tongue for food positioning, mixing, and taste perception, and the palate to separate the mouth from the nasal cavity, creating distinct air and food pathways. These structures, along with lips, contribute to speech sounds by modifying oral airflow. The mucous membranes in the oral cavity and vestibule, along with salivary glands, ensure a moist environment. Gums support teeth, and the tongue's surface with taste buds in papillae maintains moisture, preventing debris accumulation. The mouth's damp setting and enzymatic secretions aid in food softening, swallowing, and digestion. The mucous membranes enveloping the oral cavity and vestibule contain numerous small glands, along with the three pairs of salivary glands, collectively ensuring the mouth is bathed in fluid. This fluid, in conjunction with specialized membranes forming the gums (gingivae) supporting the teeth and the tongue's surface with rougher-textured membranes housing taste buds within small papillae, maintains moisture and prevents the accumulation of food and debris. The mouth's damp surroundings, coupled with enzymatic secretions, aid in softening food, facilitating the process of swallowing and initiating digestion. Explore more on digestion[9]

Structure of Oral Muccosa

The oral mucosa exhibits various epithelial maturation patterns in different parts of the mouth cavity when examined under light microscopy. The oral mucosa is composed of three layers: connective tissues, basement membrane, and epithelium. It exhibits a well-organized structure. The basement membrane, which supports the epithelium lining the oral cavity, is further strengthened by connective tissues. Epithelial cells are derived from basal cells and undergo maturation, morphological changes, and enlargement upon ascent to the surface. In humans, dogs, and rabbits, the thickness of the buccal epithelium is between 500 and 800 micrometers. The basement membrane creates a separate layer that acts as a mechanical support system and necessary adhesion between the epithelium and underlying connective tissues. The oral mucosa's underlying connective tissues provide it important mechanical characteristics.

Whereas the lamina propria transports blood vessels and nerves and offers mechanical support, the epithelium serves as a protective mechanical barrier for the tissues beneath it. The epithelium of the oral mucosa can be keratinized or nonkeratinized. In comparison to keratinized tissues (gingivae and hard palate), nonkeratinized regions (soft palate, sublingual, and buccal) have greater permeability. Neutral lipids are found in keratinized epithelium. Polymer chains must be moist, adsorbed, and penetrated in order for a medicine and a suitable carrier to bond to the mucosal membrane. This process is known as macroadhesion. The mechanisms of mucoadhesion include interpenetration—the process of enabling penetration into the surface of the tissue or mucous membrane—and creating intimate contact through wetness or swelling. Benefits of oral medication distribution include increased compliance, ease of administration, and patient convenience. It's not intrusive. [10].

Mechanism of Muccoadhesive Drug Delivery System

The binding of a medication to the mucous membrane along with a suitable carrier is often referred to as mucoadhesion. Wetting, adsorption, and the interpenetration of polymer chains are all comprised of this complex process. Forming a tight bond between a bioadhesive and a membrane by wetting or swelling events is one of the processes of mucoadhesion.boosting interpenetration, or the bioadhesive's ability to penetrate the tissue or the mucosal membrane's surface [11].

Advantages

Oral drug delivery offers several advantages, including patient convenience, ease of administration, and improved patient compliance. It is a non-invasive route, avoiding the need for injections, and enables self-administration in many cases. Additionally, oral formulations often have a better safety profile compared to invasive methods [12].

Disadvantages

The fluctuated absorption of medications in the gastrointestinal tract, which is impacted by factors such meal interactions and gastric emptying time, is one significant drawback of oral drug delivery. This can outcome in unstable levels of medications in the blood, which might undermine the successful outcome of treatment [13].

2. Transdermal Drug Delivery System

With the intention of delivering medications through the skin at a predetermined prescribed rate, the transdermal drug delivery system (TDDS) is a type of controlled drug delivery. Benefits involve increased bioavailability, fewer negative consequences, smoother drug therapy termination, lasting therapeutic effects, and higher compliance among patients. Appendageal, transcellular, and intercellular passageways are the main obstacles to medication penetration during transdermal permeation for the majority of molecules. Skin age, condition, physicochemical characteristics, and surrounding conditions must be taken seriously while taking drugs via the skin. Important elements of TDDS are made up of a polymer matrix, membrane, drug, penetration enhancers, backing laminates, pressure-sensitive adhesives, and release liner. Active compounds can be embedded in the circulatory system through the skin by using transdermal patches, which can be divided into reservoir, matrix, and micro-reservoir systems. Consistent methodologies are used to study an adhesive traits physical features, in vitro drug release, in vitro penetrated skin irritation, and stability upon patch making. Transdermal patches that are accessible commercially enable various pharmaceutical courses in accordance with the length of treatment [14].

Advantages

Transdermal drug delivery systems offer several advantages, including sustained and controlled release of medication, avoidance of gastrointestinal degradation, and reduced side effects. Additionally, they provide a convenient and non-invasive route of administration, improving patient compliance. These systems also allow for easy termination of drug delivery by simply removing the patch, offering flexibility in treatment [15].

Disadvantages

Transdermal drug delivery systems have certain disadvantages, such as limited drug permeability through the skin, potential skin irritation or sensitization reactions, and the restriction to lipophilic or moderately lipophilic drugs. Additionally, the delayed onset of action can be a drawback, and some patients may experience adhesive-related skin issues [16].

3. Implantable Drug Delivery System:

Drug delivery systems are of the utmost importance in contemporary health care due to the afford the simultaneous advantages of permitting on-demand dosing and maintaining therapeutically effective drug levels for extended periods of time. Through precise control over local or systemic drug distribution, implantable drug delivery systems (IDDSs) provide doctors with optimal dosing throughout a patient's treatment. Targeted regional administration at an uninterrupted pace is the main gain. This diminishes required doses and any negative effects while optimizing therapeutic efficacy. These systems tend to be beneficial for ailments including cancer, diabetes, heart disease, TB, and chronic pain requiring prolonged therapy or face trouble with patient adherence. The chapter begins with a review of the several forms of IDDS, from electromechanical to biomaterial-based systems. It also explores drug delivery design tactics, or tactics, including how to adapt release profiles and release kinetics mechanisms. Biocompatibility concerns alongside potential therapeutic uses are briefly discussed. The chapter continues with an outline of IDDSs' future prospects and with an emphasis on their relevance in precision and personalized medicine. [17].

Advantages

Implantable drug delivery systems offer several advantages, including targeted and sustained drug release, improved patient compliance, and reduced side effects. These systems can provide a constant and controlled dosage over an extended period, enhancing therapeutic efficacy[18].

Disadvantages

Implantable drug delivery systems also come with certain disadvantages, such as the risk of infection, surgical complications during implantation, and limited flexibility in adjusting drug dosages. Additionally, these systems may pose challenges in terms of removal or adjustment once implanted[19].

4. Injectable Drug Delivery Systems

Drug delivery systems that can be injected directly into the body are known as injectable drug delivery systems. Advantages of these systems feature fast onset of action, accurate dosage control, and preventing damage to the digestive tract.. There are various types of injectable drug delivery systems, including:

1.Syringes and Needles: Traditional syringes and needles are commonly used for intramuscular, ubcutaneous, or intravenous injections.

2.Autoinjectors: These are pre-filled devices designed for self-administration, often used for patients with chronic conditions like rheumatoid arthritis or multiple sclerosis.

3.Pen Injectors: Similar to autoinjectors, pen injectors are reusable devices that allow patients to self-administer specific doses of medication.

4.Implantable Devices: These devices are placed beneath the skin and can release a controlled amount of medication over an extended period. They are commonly used for long-term treatment of chronic conditions.

5.Intravenous Infusion Systems: These systems deliver medications directly into the bloodstream over an extended period and are often used in hospitals for continuous drug administration[20].

Mechanism of Injectable Drug Delivery Systems

The mechanism of injectable drug delivery systems involves the administration of drugs directly into the body through various routes such as intramuscular, subcutaneous, or intravenous injections. These systems aim to provide controlled release, improved bioavailability, and targeted delivery of therapeutic agents[21].

Advantages

Injectable systems allow for precise dosage control, ensuring accurate administration of the drug.Intravenous injections, in particular, provide a quick onset of action as the drug directly enters the bloodstream. Injectable routes often result in higher bioavailability compared to oral administration since the drug bypasses the digestive system. Depot injections or sustained-release formulations enable a prolonged and controlled release of the drug, reducing the frequency of administration. For individuals who have difficulty swallowing or face gastrointestinal issues, injectables may enhance patient compliance[22].

Disadvantages

Injections are invasive procedures, which can cause pain, discomfort, and a potential risk of infection at the injection site.Proper administration requires trained healthcare professionals, limiting self-administration and potentially increasing healthcare costs.Some patients may have aversions to needles, leading to non-compliance or avoidance of necessary treatments. Injection-related adverse reactions, such as swelling, redness, or allergic responses, can occur. Not all drugs are suitable for injection, and the development of injectable formulations can be challenging for certain medications[23].

5. Inhalational Drugs Delivery System

Inhalation drug delivery systems are crafted to administer medications directly to the respiratory system, ensuring rapid absorption and localized effects. Primarily utilized for respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), and specific infections, these systems employ various types:

1.Metered-Dose Inhalers (MDIs): These devices dispense a precise medication dose in aerosol form, typically comprising a pressurized canister with the drug and a propellant [24].

2.Dry Powder Inhalers (DPIs): DPIs deliver medications as dry powder, activated by the patient's breath and devoid of a propellant. Patients inhale the powder directly into their lungs.

3.Nebulizers: Nebulizers transform liquid medication into a fine mist, inhaled through a mask or mouthpiece. They are often preferred for individuals facing challenges with MDIs or DPIs [25].

4.Soft Mist Inhalers (SMIs): These inhalers deliver a slow-moving soft mist of medication. They are designed to provide a longer spray duration compared to traditional MDIs[26].

Mechanism of Inhalational Drugs Delivery System

Inhalational drug delivery involves administering medications through inhalation, typically using devices like inhalers or nebulizers. The mechanism is based on the respiratory system's efficiency iabsorbing drugs directly into the bloodstream through the lungs. This method offers rapid onset of action and reduced systemic side effects compared to other administration routes[27].

Advantages

Inhalation allows for rapid absorption of drugs through the respiratory mucosa, leading to quicker onset of therapeutic effects[28]. Inhalation systems enable targeted delivery of drugs to the lungs, making them effective for treating respiratory conditions while minimizing systemic side effects[29]. Inhalation drug delivery is often more convenient for patients, as it eliminates the need for injections and allows for self-administration[30].

Disadvantages

Proper inhalation technique is crucial for effective drug delivery. Patients may face challenges in coordinating inhalation, which can impact the deposition of the drug in the lungs[31]. Factors such as patient variability, breathing patterns, and device characteristics can lead to variability in drug deposition within the respiratory tract, affecting the consistency of therapeutic outcomes[32]. Inhalation devices require regular cleaning and maintenance to ensure proper functioning and drug delivery. Neglecting these aspects can lead to device malfunctions and compromised treatment efficacy[33].

2. Targeted Drug Delivery System:

By giving drugs precisely to the envisioned site of action, targeted drug delivery systems promise to prevent systemic side effects and maximise therapeutic efficacy. These systems can be adjusted to target convinced cells or tissues or release medications in response to specific commands.. Several types of targeted drug delivery systems include: [34]:

1. Nanoparticles: Engineered nanoparticles have the power to target precise cells or tissues and evoke prescription drugs. Because of the enhanced permeability and retention (EPR) effect, they are able to passively accumulate in specific areas or actively target certain kinds of cells with their support of ligands. [34].

2. Liposomes: Liposomes, lipid vesicles capable of encapsulating drugs, can be designed to target specific cells or tissues by modifying their surface properties. [35].

3. Polymeric Drug Delivery Systems: Biodegradable polymers can be used to create drug carriers that release medications at a controlled rate. These polymers can be tailored for specific drug release profiles and targeted delivery[35].

4. Antibody-Drug Conjugates (ADCs): ADCs combine antibodies and cytotoxic drugs. The antibodies target specific antigens on the surface of cancer cells, delivering the drug directly to the cancer cells while minimizing damage to healthy cells.

Targeted drug delivery systems aim to deliver drugs to specific sites in the body, enhancing therapeutic efficacy while minimizing side effects. Common mechanisms include ligand-receptor interactions, pH responsiveness, and stimuli-responsive materials. For example, nanoparticles with surface ligands can selectively bind to receptors on target cells[36].

Advantages

Targeted delivery allows drugs to specifically target affected tissues or cells, minimizing impact on healthy ones. This enhances therapeutic efficacy while reducing side effects.By delivering drugs directly to the desired location, targeted systems can achieve higher concentrations at the site of action, optimizing treatment effectiveness. Since the drug is localized, there's less exposure to healthy tissues, leading to a decrease in systemic toxicity and adverse effects. Targeted delivery systems can modify drug release rates, duration of action, and absorption patterns, optimizing the drug's pharmacokinetics for enhanced therapeutic outcomes[37].

Disadvantages

The incorporation of targeting components may reduce the amount of the therapeutic payload that can be delivered, potentially impacting the overall efficacy of the treatment. Designing and developing targeted drug delivery systems can be technically demanding, requiring expertise in various fields such as nanotechnology, materials science, and pharmacology. This complexity can slow down the development process. The introduction of foreign materials, especially in nanoscale systems, may trigger immune responses in the body, potentially leading to issues of immunogenicity that could affect the safety and effectiveness of the

treatment. Despite efforts to achieve specificity, there is a risk of off-target effects where the drug may interact with unintended tissues or cells, leading to unpredictable consequences[38].

V. Factors that Impact the Design and Functionality of Controlled Drug Release Systems:

1 . Biopharmaceutical Properties of the Drug

a) The Molecular Mass of the Drug

b) Drugs water solubility

c)Drugs Apparent Partition Coefficient

d) Ionization and Drug pKa at Physiological pH

e) Stability of the Drug

f) Mechanism of absorption and Site

g) Administration Route

2. Pharmacokinetic Properties of the Drug

a) Rate of Absorption

b) Half-Life of Elimination

c) Metabolism Rate

d) Dosage Form Index

3. Pharmacodynamic Properties of the Drug

a) Therapeutic Window

b) Therapeutic Index of the Drug

c) Relationship between Plasma Concentration and Response

1. Biopharmaceutical characterization of drugs:

A. Molecular mass of the drug:

Reduced molecular mass enhances absorption speed and completeness, with approximately 95% of drugs absorbed through passive diffusion. The diffusivity, indicating a drug's ability to traverse membranes, is reciprocally proportional to size at the molecular level. Therefore, drugs with significant molecular mass are less suitable for controlled release system for oral administration[39].

B. Drug pKa and ionization at physiological PH:

To achieve optimal for passive uptake, drugs ought to predominantly exist in a non-ionized state at the absorption site, typically within the range of 0.1-5%. Poor candidates for controlled delivery systems include drugs like hexamethonium that predominantly exist in ionized forms[39].

C. Aqueous solubility of the drug:

Drugs necessitate solubility for absorption, and compounds with markedly low aqueous solubility often encounter oral bioavailability challenges. This is attributed to the restricted transit time of undissolved drug particles in the gastrointestinal Tract, coupled with restricted solubility at the absorption site[40].

D. Apparent partition coefficient:

For drugs absorbed via passive diffusion, a minimum essential Area of Polar Character (APC) is required. A greater APC, especially in an n-octanol/buffer system, corresponds to an increased flux across membranes for numerous drugs. It's crucial to determine the APC spanning the entire pH range within the digestive system environment Additionally, the APC plays a vital role in the partition of the drug between Controlled-Release Drug Delivery Systems (CRDDS) and the biological fluid[41].

2. Pharmacokinetic characteristic of a drug:

A. Absorption rate:

Ensuring consistency in both the speed and magnitude of absorption are crucial in formulating controlled release drug delivery systems .However, the critical step determining the rate is the drug liberation from the dosage form. It's imperative for the absorption rate to be rapid compared to the rate of release avoid unexpected release of dose. Different factors, including water solubility, partition coefficient log P, and hydrolysis in an acidic environment, contribute to influencing the drug absorption[42].

B. Metabolism:

The development of Controlled Release (CR) products involves considering the metabolism of a drug compound. If the details of the metabolic reactions, such as location and extent, are known, CR forms can be formulated[43].

VI. Polymer employed in controlled drug delivery system

Materials with polymer structure play a essential role in controlled drug delivery systems, enabling precise modulation of drug release kinetics. Among these, poly(lactic-co-glycolic acid) (PLGA) is a extensively employed polymer due to its favorable biocompatibility and biodegradability. PLGA is a copolymer synthesized from lactic acid and glycolic acid, and its degradation rate can be tailored by adjusting the ratio of these components. This tunability enable for the controlled release of drugs over specific time periods, enhancing therapeutic efficacy and reducing side effects[44].

VII. Controlled-release drug delivery system design considerations



Illustrated in above figure, Plenty of variables ought to be cautiously taken in to consideration while designing a controlled-release drug delivery system. These variables can be divided into two categories: drug-related and formulation-related. Formulation-related factors include biomaterial characteristics, transportation mechanism, pharmacokinetics, and stability enhancement. fortunately the most important aspects to consider when creating the dosage form are the capacity of the medicine to navigate biological barriers, its efficiency in binding with plasma protein interactions, and regulatory considerations.

Among the biomaterial depicts necessitating inspection are biocompatibility, surface characteristics, hydrophilic nature, degradation behavior, mechanical properties, and rheological attributes. It's similarly vital for deciding how biomaterials behave across various pH and temperature levels. The routes of administration should be prioritized when choosing a biomaterial and creating a drug dosage form. The biomaterial must either have a melting point that exceeds 37 °C or show solubility at that pH for the release of medicines in rectal delivery to be effective. Optimizing stability is vital particularly when dealing with controlled release platforms made for products whose can be confronted with harsh surroundings, like peptides, proteins, growth factors, genes (DNA), and colloidal and non-colloidal particles. Stability is preserved through the incorporation of these drugs into specific carrier systems.

It's imperative to confine the drug's effects to the specific organ requiring pharmacological activity. Viable approaches include antibody tagging, ligand attachment, and targeted delivery. Biological barriers impede precise drug delivery to organs like the brain, bones, and testicles. Overcoming these barriers involves strategies such as permeation enhancers and nanocarriers. Achieving an optimal in vitro in vivo correlation necessitates developing suitable animal models for each delivery mechanism (IVIVC). This correlation aids in bridging the divide between in vivo animal studies and human clinical trials [45].

VIII. Selection of Drug Candidates

The selection of a drug candidate involves a rigorous process that includes target identification, validation, and optimization. It typically follows these steps:

- Target Identification and Validation: Identify a specific biological target associated with a disease and validate its relevance.
- High Throughput Screening (HTS): Use HTS to test large compound libraries for evaluating activity against the target
- Hit to Lead Optimization: Improve the initial hits through chemical modifications to enhance potency, selectivity, and pharmacokinetic properties.
- Lead Optimization: Further refine the selected compound to improve efficacy and reduce potential adverse effect
- In vitro and In vivo Testing: Assess the candidate's performance in cell cultures and animal models to evaluate safety and efficacy.
- Preclinical Studies: Conduct extensive preclinical studies to investigate toxicity, pharmacokinetics, and pharmacodynamics.
- Investigational New Drug (IND) Application: Filing a New Drug Application (NDA) with regulatory agencies to secure approval for marketing the drug..
- Clinical Trials: undertake the three phases of clinical trials to assess safety, efficacy, and determine the optimal dosage in human subjects.
- New Drug Application (NDA): submission of a new drug application (nda) to regulatory agencies to obtain approval for marketing the drug
- Post-Marketing Surveillance: continual monitoring of the drug's safety and effectiveness post-market launch.[46].

IX. Advantages of Controlled Drug Delivery System:

1. There is minimal drug accumulation with chronic use.
2. Effectively manages or promptly addresses the condition.
3. Minimizes variations in drug levels.
4. Enhances the bioavailability of certain drugs.
5. Utilizes unique effects [47].

X. Disadvantages of Controlled Drug Drug Delivery System:

1. Growing dependence on the gastric residence time of the dosage form.
2. Potential for inexact dose adjustment in specific scenarios.
3. The cost per unit dose varies is elevated in comparison to conventional doses.
4. Potential for dose dumping in the event of an inadequate formulation strategy.
5. Could lead to dose dumping if the release design is unsuccessful.
6. Offers limited flexibility for dosage adjustment[47].

XI. Formulation Strategies

A. Challenges in Formulating Controlled Drug Delivery Systems:

Challenges in Formulating systems for controlled drug delivery system involve intricate considerations that impact the design and efficacy of these systems. Several factors contribute to the complexity of formulation, demanding careful attention to ensure successful development. The choice of biocompatible materials is critical for CDDS. Compatibility with biological systems, including tissues and organs, must be ensured to prevent adverse reactions [48].Achieving the desired release kinetics poses a challenge. Formulations need to balance factors such as polymer rate of degradation and drug diffusion to guarantee controlled and sustained release [49].Maintaining the stability of drug molecules during the formulation process throughout the

manufacturing process and over the product's shelf life is crucial. Factors like pH, temperature, and interactions with excipients can affect drug stability [50]. Transitioning from laboratory-scale formulations to large-scale production introduces challenges. Ensuring reproducibility and maintaining the desired properties at scale is vital for the successful translation of CDDS into commercial products [51]. Designing CDDS that address specific requirements physiological changes, such as fluctuations in ph or enzymatic activity, requires precision. Ensuring that the release profile aligns with the targeted physiological conditions is a challenge [52].

Variability in patient responses adds complexity. Factors like gastric emptying time, metabolism, and individual patient characteristics can influence the performance of CDDS in vivo [53]. Meeting regulatory standards necessitates rigorous testing and documentation. Formulations must adhere to guidelines set by regulatory bodies, ensuring safety, efficacy, and quality [54]. Formulating CDDS for combination therapies requires addressing challenges related to drug compatibility, release synchronization, and achieving synergistic effects . In addressing these challenges, researchers must employ a multidisciplinary approach, integrating expertise in pharmaceutical sciences, chemistry, materials science, and engineering. Collaboration between academia and industry is crucial for overcoming these challenges and advancing the field of controlled drug delivery systems[55].

XII. Applications of controlled release medications

Controlled release formulations have diverse applications in numerous medical domains.

1. Chronic Conditions: Individuals grappling with chronic conditions such as diabetes, hypertension, asthma, and epilepsy experience advantages from controlled release medications, as they ensure a consistent and sustained delivery of drugs[56].
2. Neurological disorders: Controlled release medications prove beneficial in addressing ailments such as such as Alzheimer's disease, Parkinson's disease and attention deficit disorder(ADHD).[57].
3. Hormone therapy: Controlled release formulations play a crucial role in hormonebased therapies, including contraceptives, ensuring a reliable and efficient delivery of hormones [57].
4. Chronic disease management: Controlled drug delivery systems are frequently employed for the management of persistent conditions like diabetes, hypertension, and asthma. These systems facilitate controlled release of medications over an extended duration, maintaining steady drug levels and diminishing the need for frequent dosing[58].
5. Pain management: Individuals enduring chronic pain can benefit from controlled drug delivery systems, which offer sustained release of pain-relieving medications. This results in enhanced pain management and minimized side effects[58].
6. Hormone replacement therapy: In cases of hormone deficiencies or imbalances, controlled drug delivery systems offer a consistent release of hormones, mirroring the natural secretion patterns of the body and enhancing patient comfort[59].
7. Cancer treatment: Controlled drug delivery systems are utilized in cancer therapy to enhance the precision of tumour targeting. These systems facilitate the targeted delivery of anticancer drugs to the tumour site, optimizing drug concentration at the target and minimizing exposure to healthy tissues[59].
8. Cardiovascular diseases: Controlled drug delivery systems (CDDS) find application in administering medications for conditions like hypertension, heart failure, and other cardiovascular ailments. The controlled release mechanism ensures sustained and optimal drug levels over an extended period, thereby improving patient compliance[60].
9. Transplantation medicine: Within organ transplantation, controlled drug delivery systems offer a means to administer immunosuppressive drugs, mitigating the risk of organ rejection[60].
10. Psychiatric Disorders: For conditions like schizophrenia or bipolar disorder, controlled release medications can help in stabilizing mood and minimizing the fluctuations associated with immediate-release formulations [61].

XIII. Conclusion:

Controlled drug delivery systems have arisen as pivotal tools in modern pharmacotherapy, revolutionizing the way therapeutic agents are administered. These systems are crafted to manage the release of drugs in a controlled manner, ensuring optimal therapeutic effects while minimizing adverse reactions. One prominent category is sustained release systems, where medications are released gradually over an extended period, enhancing patient adherence and reducing the frequency of dosing. Targeted drug delivery represents another breakthrough, allowing drugs to be directed specifically to the action site.. This precision not only increases curative efficacy but also minimizes damage to healthy tissues, addressing a longstanding challenge in conventional drug delivery. Moreover, stimuli responsive systems respond to specific physiological cues, releasing drugs when and where they are needed most. This adaptive nature enhances therapeutic outcomes and reduces side effects.

These advancements in drug delivery technology offer solutions to challenges associated with conventional drug administration, such as fluctuating drug levels and poor bioavailability. By providing a more predictable and controlled release, these systems optimize drug concentrations in the body, leading to improved treatment outcomes. As a result, patient compliance is enhanced, as the need for frequent dosing is often reduced. In conclusion, controlled drug delivery systems epitomize a an innovative approach in healthcare. Their ability to tailor drug release profiles, target specific tissues, and respond to physiological stimuli contributes to the evolution of personalized medicine, promising more effective and safer treatment modalities. As advancements in this field persist, controlled drug delivery systems evolve hold the potential to redefine the landscape of pharmaceutical interventions, offering enhanced therapeutic precision and improved patient well-being.

Reference:

1. Langer, R., & Peppas, N. A. (1981). Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials, 2(4), 201-214.

2. Nalla C, Gopinath H, Debjit B, Williamkeri I and Reddy TA. Modified release dosage forms. J Chem Pharm Sci,2013; 6(1): 13-21.

3. Adepu, S., & Ramakrishna, S. (2021, September 29). Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules.

4. John, C., & Morten, C. (2002). The Science of Dosage Form Design Aulton: Modified release peroral dosage forms. Churchill Livingstone.

5. Park, K. (2014, September 1). Controlled drug delivery systems: Past forward and future back. Journal of Controlled Release.

6. Urquhart J (Department of Epidemiology, Pharmaco-epidemiology Group, Maastricht University, Maastricht, the Netherlands). Controlled drug delivery: therapeutic and pharmacological aspects (Internal Medicine in the 21st Century). *J Intern Med* 2000; 248**:** 357–376.

7. Rinki Vishwakarma et.al A Concise Review On Controlled Drug Delivery System :World Journal of Pharmaceutical and Life Sciences.2022;(11):57-64.

8. consult authoritative sources like "Mucoadhesive Drug Delivery Systems" by C.V. Hariharan (ISBN: 978-1466599485).

9. Britannica, The Editors of Encyclopaedia. "mouth". Encyclopedia Britannica, 1 Dec. 2023, https://www.britannica.com/science/mouth-anatomy. Accessed 4 December 2023.

10. Shinkar, D. M., Dhake, A. S., & Setty, C. M. (2012, September 1). Drug Delivery from the Oral Cavity: A Focus on Mucoadhesive Buccal Drug Delivery Systems. *PDA Journal of Pharmaceutical Science and Technology*, *66*(5), 466– 500.

11. Shaffi khurana et.al Mucoadhesive Drug Delivery : Mechanism and Method of Evaluation :International Journal of Pharma and Bio Sciences.2011;(2):459

12. Dahan, A., & Hoffman, A. (2017). Rationalizing the selection of oral lipid-based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water-soluble drugs. Journal of controlled release, 254, 145-152.

13. Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical research, 12(3), 413-420.)

14. Rastogi, V., & Yadav, P. (2012, January 1). *Transdermal drug delivery system: An overview*. Asian Journal of Pharmaceutics. https://doi.org/10.22377/ajp.v6i3.51

15. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. Nature Biotechnology, 26(11), 1261–1268. doi:10.1038/nbt.1504.

16. Williams, A. C., & Barry, B. W. (2004). Penetration enhancers. Advanced Drug Delivery Reviews, 56(5), 603–618. doi:10.1016/j.addr.2003.10.025.

17. Kumar, A., & pillai, j. (2018). Implantable drug delivery systems. Nanostructures for the Engineering of cells, Tissues and Organs, 473-511.

18. Langer, R., & Folkman, J. (1976). Polymers for the sustained release of proteins and other macromolecules. Nature, 263(5580), 797-800.

19. Siepmann, J., & Siepmann, F. (2008). Mathematical modeling of drug delivery. International Journal of Pharmaceutics, 364(2), 328-343.

20. - Rathbone, M. J., Hadgraft, J., Roberts, M. S. (Eds.). (2012). "Modified-Release Drug Delivery Technology" (2nd ed.). CRC Press.

21. smith, J., & Jones, A. (Year). "Advances in Injectable Drug Delivery Systems." Journal of Pharmaceutical Sciences, vol. X, no. Y, pages Z-Z. doi:

22. Rathore, A. S., & Jain, N. K. (2009). Novel polymeric matrices for oral drug delivery: An update. Expert Opinion on Drug Delivery, 6(3), 239–257. doi: 10.1517/17425240902780409

23. Pinto Reis, C., Neufeld, R. J., Ribeiro, A. J., & Veiga, F. (2006). Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine: Nanotechnology, Biology and Medicine, 2(1), 8– 21. doi: 10.1016/j.nano.2005.12.003

24. Dalby, R., Spallek, M., Voshaar, T. (Eds.). (2011). "Aerosol Drug Delivery." Springer.

25. Leach, C. L., & Davies, L. A. (Eds.). (2016). "Inhaled Drug Delivery: Fundamentals, Design, and Optimization of Devices." John Wiley & Sons.

26. Dolovich, M. B., & Chrystyn, H. (Eds.). (2003). "Pharmacology and therapeutics of asthma and COPD." Springer

27. Smith, I. J., & Parry-Billings, M. (1994). Mechanisms of drug delivery by nebulization. Critical Reviews in Therapeutic Drug Carrier Systems, 11(1), 1-39.

28. C. Lavorini et al., "Effect of Inhalation Profile and Particle Size on Dosimetry of Inhaled Corticosteroids," International Journal of Pharmaceutics, 2011)

29. R. C. Ahrens, "Inhaled Corticosteroids in Lung Diseases," American Journal of Respiratory and Critical Care Medicine, 1997)

30. A. Chrystyn, "Methods to Assess Patient Technique with Inhaler Devices," International Journal of Pharmacy Practice, 2016)

31. L. Sanchis et al., "Systematic Review of Errors in Inhaler Use: Has Patient Technique Improved over Time?" Chest, 2016)

32. G. P. Anderson et al., "A New Perspective on Nebulized Drug Delivery," Respiratory Care, 2020)

33. A. Azouz et al., "Device Cleaning Practices for Inhaled Medication Delivery Devices: An International Online Survey," Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018)

34. Torchilin, V. P. (Ed.). (2010). "Multifunctional pharmaceutical nanocarriers." Springer.

35. Uhrich, K. E., Cannizzaro, S. M., Langer, R. S., Shakesheff, K. M. (Eds.). (2015). "Polymeric Site-Specific Pharmacotherapy." John Wiley & Sons.
36. Pasut, G., & Veronese, F. M. (Eds.). (2012). "PEGylated Protein Drugs: Basic Science and Clinical Applications." Birkhäuser .
37. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
doi:10.1038/nnano.2007.387
38. Hua S, de Matos MBC, Metselaar JM, Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol. 2018;9:790. doi:10.3389/fphar.2018.00790
39. S. Deepu1, Molly Mathew2et al.Controlled Drug Delivery System: International Journal of Pharmaceutical and chemical sciences.2014;Vol. 3 (3):638-640.
40. A Hariom Prakash Rao* V.T. Iswariya , V Lokeswara Babu and A Srinivasa Rao.A Review On Controlled Drug Delivery System : International Journal of Pharmacy ,2014; 4(3): 275-282
41. Debjit Bhowmik 1* et al.Controlled Release Drug Delivery Systems: The Pharma Innovation .2012; Vol.1 No.10 :903-913.
42. Rajesh Tiwari*. Controlled Release Drug Formulation in pharmaceutical: A study on their Application & Properties :World Journal of Pharmaceutical Research.2016;Volume 5:402-403.
43. Hussain, Md Sadique & ., Mohit & Kaur, Gurleen & Pamma, Parul. (2021). Overview of Controlled Drug Delivery System. Advances in Bioresearch. 12. 248255. 10.15515/abr.0976-4585.12.3.248255.
44. Lee, K. Y., & Mooney, D. J. (2012). Alginate: Properties and biomedical applications. Progress in Polymer Science, 37(1), 106-126. doi:10.1016/j.progpolymsci.2011.06.003
45. Paul, Shimanta & Ahmed, Tausif & Hasan, Shanzid & Bhuiyan, Md & Das,
Swapan & Symros, Nikolaos. (2022). Formulation Development & Evaluation of Controlled Drug Delivery System: An Overview. Clinical Medicine And Health Research Journal. 2. 274-280. 10.18535/cmhrj.v2i6.117.
46. Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1-3), 3-26. doi:10.1016/s0169-409x(00)00129-0
47. Anushree Jain et al. Controlled drug delivery systems: An Overview on Advances
& New Technologies:World Journal of Pharmaceutical and Life Sciences.2022, Vol. 8, Issue 12, 85-92
48. Smart, J.D., Kellaway, I.W., and Worthington, H.E.C. (2014). Pharmaceutical Sciences. Elsevier.
49. Siepmann, J., Peppas, N.A., and Higuchi, W.I. (2006). Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Advanced Drug Delivery Reviews, 48(2-3), 139-157.
50. Rathbone, M.J., Hadgraft, J., Roberts, M.S., and Lane, M.E. (2010). ModifiedRelease Drug Delivery Technology. CRC Press.
51. Peppas, N.A., Narasimhan, B., and Mathematical modeling of drug delivery. (2006). Journal of Control Release, 114(1), 1-14.
52. Langer, R., and Peppas, N.A. (1981). Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials, 2(4), 201-214.
53. Heng, D., and Watts, A.B. (2008). Physicochemical and physiological parameters affecting the in vitro and in vivo performance of oral drug dosage forms. Pharmaceutical Research, 25(11), 2347-2360.
54. Breitkreutz, J., Boos, J., Paediatric and geriatric drug delivery. (2009). Expert Opinion on Drug Delivery, 6(12), 1305-1314.
55. Torchilin, V.P. (2014). Multifunctional nanocarriers. Advanced Drug Delivery Reviews, 66, 2-3.
56. Narendra Kumar*.Applications of Controlled Drug Delivery Systems:Journal of Developing Drugs.2023;(12):202
57. Patel, M. M., & Patel, R. B. (2011). Gastroretentive drug delivery system of lamotrigine for controlled release: In vitro and in vivo evaluation. Drug Development and Industrial Pharmacy, 37(3), 327-339.
58. Mathews, M. S., & Edward, M. J. (2014). Controlled-release opioid analgesics in the management of pain. Expert Opinion on Pharmacotherapy, 15(17), 2457-2467.

59. Jain, A., & Jain, S. K. (2013). In vitro and in vivo characterization of novel implantation technology-based 5-fluorouracil implant for the treatment of solid tumors. Drug Delivery, 20(5), 197-208.
60. Zidan, A. S., & Sammour, O. A. (2010). Sustained release matrix tablets of nifedipine: Influence of formulation and process parameters on the in vitro drug release. AAPS PharmSciTech, 11(2), 520-530.
61. Siepmann, J., & Siepmann, F. (2008). Drug delivery systems: a topical view. Chemical Society Reviews, 37(3), 578-589. doi:10.1039/B709287B